KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bionano Genomics (BNGO) Other Non-Current Liabilities (2017 - 2024)

Bionano Genomics' Other Non-Current Liabilities history spans 6 years, with the latest figure at $5.8 million for Q2 2024.

  • For Q2 2024, Other Non-Current Liabilities fell 60.37% year-over-year to $5.8 million; the TTM value through Jun 2024 reached $5.8 million, down 60.37%, while the annual FY2023 figure was $10.9 million, 16.04% down from the prior year.
  • Other Non-Current Liabilities for Q2 2024 was $5.8 million at Bionano Genomics, down from $10.2 million in the prior quarter.
  • Across five years, Other Non-Current Liabilities topped out at $14.9 million in Q3 2023 and bottomed at $75000.0 in Q3 2020.
  • The 5-year median for Other Non-Current Liabilities is $10.6 million (2023), against an average of $9.2 million.
  • The largest annual shift saw Other Non-Current Liabilities soared 209.33% in 2021 before it crashed 60.37% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $75000.0 in 2020, then skyrocketed by 11988.0% to $9.1 million in 2021, then soared by 43.06% to $13.0 million in 2022, then fell by 16.04% to $10.9 million in 2023, then plummeted by 46.98% to $5.8 million in 2024.
  • Per Business Quant, the three most recent readings for BNGO's Other Non-Current Liabilities are $5.8 million (Q2 2024), $10.2 million (Q1 2024), and $10.9 million (Q4 2023).